 WARMER, Pa. and OXFORD, United Kingdom, July 06, 2021 GLOBE NEWSWIRE -- Arbutus Biopharma Corporation Nasdaq: ABUS and Vaccitech plc Nasdaq: VACC today announced that the companies have entered into a clinical trial collaboration agreement to evaluate an innovative therapeutic combination for the treatment of subjects with chronic hepatitis B virus HBV infection CHB who are already receiving standard-of-care nucleostide reverse transcriptase inhibitor NrtI therapy. 